The Special Approval Pathway (SAP) for COVID-19 related products in China

August 21, 2020

Since the COVID-19 pandemic began in early 2020, the Center for Drug Evaluation (CDE) has maximized its capacity and optimized its regulatory procedures within the SAP framework to accelerate COVID-19 related drug development.

Previous Article
I Can See More Clearly Now – FDA Issues Needed Guidance on Inspection Policies During COVID-19
I Can See More Clearly Now – FDA Issues Needed Guidance on Inspection Policies During COVID-19

FDA has previously made several public statements about its ability to conduct inspections and FDA personne...

Next Article
NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020
NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020

Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiati...